Valiant Laboratories Limited (NSE:VALIANTLAB)
India · Delayed Price · Currency is INR 91.99
+1.14 (1.25%)
Aug 19, 2026, 3:29 PM IST
Valiant Laboratories Revenue
Valiant Laboratories had revenue of 1.15B INR in the quarter ending June 30, 2026, with 146.22% growth. This brings the company's revenue in the last twelve months to 3.06B, up 89.64% year-over-year. In the fiscal year ending March 31, 2026, Valiant Laboratories had annual revenue of 2.37B with 78.04% growth.
Revenue (ttm)
3.06B
Revenue Growth
+89.64%
P/S Ratio
1.63
Revenue / Employee
38.73M
Employees
79
Market Cap
4.99B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.37B | 1.04B | 78.04% |
| Mar 31, 2025 | 1.33B | -486.75M | -26.74% |
| Mar 31, 2024 | 1.82B | -1.52B | -45.48% |
| Mar 31, 2023 | 3.34B | 215.43M | 6.90% |
| Mar 31, 2022 | 3.12B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Windlas Biotech | 9.42B |
| Sigachi Industries | 4.76B |
| Jagsonpal Pharmaceuticals | 2.94B |
| Amanta Healthcare | 2.91B |
| Balaxi Pharmaceuticals | 2.80B |
| Sakar Healthcare | 2.72B |
| Bafna Pharmaceuticals | 1.43B |
| Par Drugs and Chemicals | 1.09B |